DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20184887

Hypofractionated radiotherapy in post mastectomy locally advanced breast cancer: a study from a regional cancer center in North East India

Mouchumee Bhattacharyya, Apurba Kumar Kalita, Partha Pratim Medhi, Vikas Jagtap, Rubu Sunku, Fahim Arman Hassan, Manoj Kalita, Manigreeva Krishnatreya, Amal Chandra Kataki

Abstract


Background: Adjuvant radiotherapy has increased local-regional and overall survival rates in breast cancer. Conventional fractionation delivering 50-60 Gray (Gy) over 5-6weeks is a standard approach. A shorter duration of hypofractionated treatment will be more convenient for patients and treatment providers if found safe and equally effective.

Methods: Around 50 high risk breast cancer patients who underwent mastectomy were enrolled and randomized into the study arms- CF (Conventional Fractionation) Arm (50Gy/25 Fr @ 2 Gy/fraction/day 5 days a week over 5weeks) and HF (Hypo-Fractionation) arm (40.05 Gy/15 Fr @ 2.67 Gy/fraction/day 5 days a week over 3weeks). Treatment related acute and late toxicities, loco-regional recurrence; distant metastasis and survival rates were recorded for comparison.

Results: Twenty-five patients were enrolled in each arm with baseline characters well matched. At median follow up of 44 months, OS was 80% in HF arm against 64% in CF arm (p-value: 0.292). HF arm also showed better DFS at 4 years of 76% compared to 64% in CF arm (p-value: 0.411). Although the difference was not significant statistically, the Hazard Ratio of 1.543 (95% CI: 0.549-4.339) for DFS and 1.801 (95% CI: 0.603-5.377) for OS indicated trends towards better outcomes in HF arm in terms of disease control and survival. Acute and late toxicities were also lesser in HF arm, though not statistically significant (all p-values >0.05).

Conclusions: In post mastectomy setting, HFRT is comparable to CFRT in terms of safety and efficacy, will be more convenient for patients and care givers and hence can be a routine standard practice.


Keywords


Breast cancer, Hypofractionation, Post-mastectomy, Radiotherapy

Full Text:

PDF

References


Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J National Cancer Institute. 2005;97(2):116-26.

Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. New Eng J Med. 1997 Oct 2;337(14):949-55.

Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. The Lancet. 1999 May 15;353(9165):1641-8.

Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b and c randomized trials. Radio Oncol. 2007;82(3):247-53.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet 2011;378:1707-16.

American College of Radiology. ACR Appropriateness Criteria®: postmastectomy radiotherapy. 2015:6.

Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010;362(6):513-20.

Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J, et al. Effect of radiotherapy fraction size on tumor control in patients with early stage breast cancer after local tumor excision: long-term results of a randomized trial. Lancet Oncol 2006;7(6):467-71.

Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet. Oncology. 2008 Apr;9(4):331-41.

Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet (London, England). 2008;371(9618):1098-107.

Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. The lancet oncology. 2013 Oct 1;14(11):1086-94.

Saxena S, Rekhi B, Bansal A, Bagga A, Murthy NS. Clinico-morphological patterns of breast cancer including family history in a New Delhi hospital, India-A cross-sectional study. World J Surg Oncol. 2005 Dec;3(1):67.

Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341-6.

El-Sayed MI, Abdel-Wanis ME. Comparison of hypofractionated and conventional radiotherapy protocols in breast cancer patients: a retrospective study. J Cancer Sci Ther. 2012;4:158-63.

Pinitpatcharalert A, Chitapanarux I, Euathrongchit J, Tharavichitkul E, Sukthomya V, Lorvidhaya V. A retrospective study comparing hypofractionated radiotherapy and conventional radiotherapy in postmastectomy breast cancer. J Med Association Thailand= Chotmaihet thangphaet. 2011 Mar;94:S94-102.

Ko DH, Norriss A, Harrington CR, Robinson BA, James ML. Hypofractionated radiation treatment following mastectomy in early breast cancer: The C hristchurch experience. J Medical Imaging Radiation Oncol. 2015 Apr;59(2):243-7.

Ali EM, AlMageed MKA. Post-mastectomy hypofractionation radiotherapy in breast cancer patients. Cancer Oncol Res. 2014;2(7):87-93.

Khan AJ, Poppe MM, Goyal S, Kokeny KE, Kearney T, Kirstein L, et al. Hypofractionated postmastectomy radiation therapy is safe and effective: first results from a prospective phase ii trial. J Clinical Oncology: official J Am Society Clin Oncol. 2017 Jun;35(18):2037-43.

Sun GY, Wang SL, Song YW, Jin J, Wang WH, Liu YP, et al. Hypofractionated radiation therapy after mastectomy for the treatment of high-risk breast cancer: 5-year follow-up result of a randomized trial. Inter J Radia Oncol Biol Phy. 2017;99(2):S3-4.